Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.6M Sell
169,593
-132,937
-44% -$15M 2.35% 15
2026
Q1
$33.7M Sell
302,530
-119,663
-28% -$14.2M 3.44% 9
2025
Q4
$56.9M Sell
422,193
-117,511
-22% -$12.8M 7.91% 1
2025
Q3
$45.8M Buy
+539,704
New +$33.1M 6.18% 1
2025
Q2
Sell
-210,901
Closed -$1.32M 66
2025
Q1
$1.32M Sell
210,901
-74,219
-26% -$502K 0.27% 57
2024
Q4
$2.09M Sell
285,120
-176,540
-38% -$1.63M 0.46% 44
2024
Q3
$5.32M Buy
461,660
+5,860
+1% +$70.2K 1.19% 30
2024
Q2
$6.03M Buy
455,800
+380,800
+508% +$5.45M 1.42% 24
2024
Q1
$1.07M Buy
+75,000
New +$967K 0.3% 60

Other funds holding ABVX

Silverarc Capital Management's ABVX Position: Q2 2026 in Review

Silverarc Capital Management reduced its Abivax (ABVX) stake by 44% in Q2 2026, selling an estimated $15M and leaving 169,593 shares worth $22.6M. The position accounts for 2.35% of the portfolio, ranked #15.

Silverarc Capital Management first reported a position in ABVX in Q1 2024 and has held it in 9 quarters since. The position peaked at $56.9M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Silverarc Capital Management held 169,593 shares of Abivax worth $22.6M as of Q2 2026.
  • Silverarc Capital Management sold 132,937 Abivax shares in Q2 2026, an estimated $15M.
  • Abivax made up 2.35% of Silverarc Capital Management's portfolio in Q2 2026, its #15 holding.
  • Silverarc Capital Management first reported a position in Abivax in Q1 2024 and has held it in 9 quarters since.
  • Silverarc Capital Management's Abivax position peaked at $56.9M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.